Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.
10.5045/kjh.2011.46.3.180
- Author:
Jae Sook AHN
1
;
Deok Hwan YANG
;
Sung Hoon JUNG
;
Soo Young BAE
;
Huong Thi TRAN
;
Hyung Chul PARK
;
Ha Na KIM
;
Yeo Kyeoung KIM
;
Hyeoung Joon KIM
;
Je Jung LEE
Author Information
1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea. drjejung@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Fludarabine;
Primary;
Lymphoma
- MeSH:
Acute Coronary Syndrome;
Anaphylaxis;
Antibodies, Monoclonal, Murine-Derived;
Cyclophosphamide;
Dexamethasone;
Disease-Free Survival;
Drug Therapy, Combination;
Follow-Up Studies;
Humans;
Intracranial Hemorrhages;
Lymphoma;
Lymphoma, Follicular;
Lymphoma, Non-Hodgkin;
Mitoxantrone;
Neutropenia;
Vidarabine;
Rituximab
- From:Korean Journal of Hematology
2011;46(3):180-185
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The clinical efficacy and safety of fludarabine combination chemotherapy was investigated for the treatment of previously untreated patients with low-grade (NHL). METHODS: Twenty-five patients who were newly diagnosed as low-grade NHL were treated with fludarabine combination chemotherapy. Fludarabine combination regimens consisted of fludarabine, mitoxantrone and dexamethasone or fludarabine, cyclophosphamide and mitoxantrone with or without rituximab and repeated every 4 weeks. RESULTS: The median age was 60 years (range, 35-77 years), with 13 of 25 patients (52%) > or =60 years of age. Seven of 25 patients (28%) with an intermediate risk follicular lymphoma international prognostic index (FLIPI) and 9 of 25 patients (36%) with a high risk FLIPI were enrolled in this study. The delivered median number of chemotherapy was six (range, 2-9 cycles). The overall response rate with fludarabine-based treatment was 88%, including 52% complete remission and 36% partial remission. During the median follow-up of 19 months, the estimated 2-year event-free survival was 63+/-10% (95% CI, 43-83) and the 2-year overall survival was 78+/-9% (95% CI, 60-96). Fludarabine combination chemotherapy was frequently associated with grade 3 or 4 neutropenia in 84% patients. However, neutropenic infection was observed in only one (4%) patient. Four patients (16%) showed grade 3 or more non-hematologic toxicities, such as acute coronary syndrome, intracranial hemorrhage, anaphylaxis and gastric cancer. CONCLUSION: Fludarabine-combination treatment was a highly active regimen with well toleration in untreated low-grade NHL.
